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Ovarian cancer constitutes the principal cause of death among
female genital malignancies. During the last years, refined and
more radical operation techniques as well as adjuvant combination
chemotherapy have significantly improved the survival of patients
with advanced ovarian cancer (Griffiths et al, 1979; Heintz et al,
1986; Bertelsen, 1990; Jänicke et al, 1992; Kuhn et al, 1993). Yet,
radical resection of the tumour mass, which so far represents the
strongest prognostic marker for survival probability, still could not
prevent disease recurrence and subsequent death in over 70% of
cases. In view of this, other prognostic markers are needed in order
to identify patients at risk, with the aim of individualizing thera-
peutic strategies. Several tumour biological factors have been
proposed and their prognostic strength evaluated including
oestrogen, progesterone and epidermal growth factor (EGF)
receptor, DNA-ploidy, S phase, and oncogenes (Friedlaender et al,
1989; Berchuck et al, 1991; Tyson et al, 1991; Lage et al, 1992).
However, due to rather controversial data obtained from studies
exhibiting great heterogeneity of cancer stages within the patient
cohorts and often enrolling low patient numbers, so far none of
these parameters has been introduced into clinical routine.
Nonetheless, increasing attention has been paid to the prognostic
impact of components of the plasminogen activator system
conductive to extracellular matrix breakdown, thereby favouring
tumour spread and metastasis (Danø et al, 1985; Schmitt et al,
1997a). Upon interaction of the serine protease urokinase plas-
minogen activater (uPA) with its receptor uPAR (CD87) on
tumour cells, plasminogen is converted to the serine protease
plasmin, thus focusing proteolytic activity to the cell surface
(Roldan et al, 1990). Enzymatic activity of uPA is regulated by the
plasminogen activator inhibitors PAI-1 and PAI-2 (Conese and
Blasi, 1995). For a large series of solid cancers, uPA and PAI-1
have been established as reliable, statistically independent prog-
nostic factors to predict recurrence-free and/or overall survival
(Jänicke et al, 1989; Duffy et al, 1990; Foekens et al, 1992;
Grøndahl-Hansen et al, 1993; Nekarda et al, 1994; Kobayashi et
al, 1994; Hofmann et al, 1996; Schmitt et al, 1997a).
So far only a few studies are available on the clinical impact of
uPA and PAI-1 in ovarian cancer (Kuhn et al, 1994; Schmalfeldt et
al, 1995; Van der Burg et al, 1996), although it has been known for
some time that ovarian cancer cells synthesize uPA and PAI-1 and
express uPAR on the cell surface (Astedt and Holmberg, 1976;
Casslen et al, 1994). In the ascitic fluid of ovarian cancer patients,
a soluble form of uPAR has been detected and characterized
(Pedersen et al, 1993). Increased uPAR in serum of ovarian cancer
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patients is associated with a poor prognosis (Sier et al, 1998).
Elevated antigen levels of uPA and PAI-1 have been determined in
invasive ovarian cancer tissue and correlated with the degree of
tumour spread (Pujade-Lauraine et al, 1993). In 1994, our group
was the first to conduct a systematic statistical analysis in patients
with advanced ovarian cancer stage FIGO IIIc proving the prog-
nostic value of elevated primary tumour tissue levels of uPA and
PAI-1 (Kuhn et al, 1994). The prospective study presented here
consolidates the strong prognostic impact of PAI-1 and residual
tumour mass in an enlarged cohort of advanced ovarian cancer
patients stage FIGO IIIc. We also investigate the time-dependence
of the strength of these prognostic factors by applying the statis-
tical model of Gray (1992).
MATERIALS AND METHODS
Patients and surgical treatment
Eighty-six patients (1986–1996) afflicted with advanced ovarian
cancer stage FIGO IIIc (Fédération Internationale de Gynécologie
et d’Obstétrique) were enrolled in a prospective study conducted
at the Frauenklinik der Technischen Universität München (Table
1). Standard surgical procedures were performed including partial
resection of the small and large intestine, diaphragmatic peri-
toneum, peritonectomies and upper abdominal surgery, as well as
pelvic and para-aortic lymphadenectomy if indicated (Kuhn et al,
1993, 1998). The aim of the surgical procedure was to remove the
entire tumour; postoperative macroscopically visible tumour was
the criterion for defining the presence or absence of residual
tumour. Seventy-three patients received standard chemotherapy
postoperatively based on platinum and/or paclitaxel. Eight patients
treated otherwise were diagnosed before 1990 and received
cyclophosphamide in a palliative fashion. Five patients did not
receive chemotherapy due to unfavourable health conditions. The
median values of follow-up were 31 months for all and 48 months
for patients still alive at time of follow-up.
Tumour tissue collection and ELISA
Tissue samples from primary ovarian cancer (n = 86) were
collected during surgery, classified by the pathologist and stored in
liquid nitrogen till use. Control tissue extracts were prepared from
20 benign ovarian tumors. Deep-frozen specimens of 200–500 mg
wet weight were pulverized using the ‘Micro-Dismembrator’
(Braun, Melsungen, Germany) and immediately suspended in 2 ml
Tris-buffered saline (TBS: 0.02 M Tris-HCl, pH 8.5, 125 mM
sodium chloride), 1% (v/v) Triton X-100 (Sigma, München,
Germany). Extraction was conducted at 4°C for 12 h followed by
ultracentrifugation at 100 000 g for 45 min to separate cell debris.
uPA and PAI-1 antigen concentrations were determined in the
supernatant by commercially available enzyme-linked
immunosorbent assay (ELISA) kits Imubind uPA #894 and
Imubind PAI-1 #821 respectively (American Diagnostica,
Greenwich, CT, USA) (Kuhn et al, 1994). Protein concentrations
were determined by the BCA protein assay procedure (Pierce,
Rockford, IL, USA). Antigen concentrations for uPA and PAI-1
are expressed as ng mg–1 of extracted tissue protein.
Statistical methods
Univariate and multivariate analyses were performed according to
the proportional hazard model of Cox using the SPSS software
package (SPSS Inc., Chicago, IL, USA). The prognostic impact
was tested using the Wald test; survival probability was calculated
according to Kaplan and Meier (1958). For quantitative parame-
ters (uPA, PAI-1, age and S phase) cut-off levels were calculated
by the CART (Classification And Regression Tree) method using
the log-rank statistic. Cutoffs with maximal log-rank statistic were
taken to discriminate between the categories ‘high’ and ‘low’ for
quantitative parameters. Significance level of differences between
the antigen levels in cancer tissues versus control tissues were
evaluated using Mann–Whitney U-test. Differences were consid-
ered to be significant if P < 0.05. A possible time variation of the
prognostic influence (relative risk) of prognostic factors was eval-
uated as described by Ulm et al (1997) and Schmitt et al (1997b),
applying the statistical framework of Gray (1992). In this applica-
tion of Gray’s framework, Cox’s proportional hazard assumption
is relaxed by introducing time-dependent coefficients b(t). Thus,
the relative risk (RR) is expressed in the form:
RR (t,x) = exp (b[t]x).
Analyses were performed using the statistical software program
S-Plus (Statistical Sciences, 1993).
Table 1 Patient data for ovarian cancer FIGO IIIc (n = 86)
Median age (range) 60 (20–82) years
Median observation time (range)
All patients 31 (1–115) months
Patients alive 48 (20–115) months
Variable n
Histology
Serous 61
Mucinous 5
Endometroid 3
Clear cell 3
Undifferentiated 14
Grading
G1 6
G2 19
G3 50
G4 11
Nodal status
N0 24
N1 46
Nx 16
Ascites volume
≤500 ml 51
>500 ml 35
Residual tumour mass
No 43
Yes 43
Lymphadenectomy
Pelvic 7
Paraaortic 4
Pelvic + paraaortic 45
Sampling 10
None 20
Chemotherapy
Platinum/paclitaxel 73
Other 8
None 51748 W Kuhn et al
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RESULTS
Prognostic impact of uPA, PAI-1 and established
prognostic factors on overall survival
uPA and PAI-1 antigen were determined by ELISA in primary
tumour tissue extracts of 86 ovarian cancer patients stage FIGO
IIIc; their prognostic impact was assessed by weighting with clin-
ical prognostic factors such as age, residual tumour mass, grading,
nodal status, ascites volume, DNA-ploidy and S phase. Of these
factors, only residual tumour mass, nodal status, grading and
ascites volume were of statistical relevance for overall survival in
univariate analysis. Macroscopically tumour-free patients (n = 43)
had a significant survival advantage (median survival time 65
months) over patients with postoperative residual tumour mass (n =
43) with a median survival time of 17 months (Figure 1). Likewise,
node-negative patients (n = 24) had a significantly better prognosis
than patients with node-positive (n = 46) or unknown nodal status
(n = 16). Patients with low-grade tumours (n = 25) as well as
patients with low ascites volume (n = 51) also had a significantly
better prognosis than patients with high-grade tumours (n = 61, P =
0.015) and elevated ascites volume (n = 35, P = 0.034) respectively.
In this group of patients, only age approached prognostic signifi-
cance (P = 0.053). DNA-ploidy and S phase, a measure of cell
cycle activity, were of no statistical relevance.
Both uPA (1.06 ng mg–1 protein, range: 0.05–8.46) and PAI-1
(14.96 ng mg–1 protein, range: 0.14–287.6) median antigen content
was significantly elevated in cancer tissues compared to benign
ovarian tumour tissues (n = 20; uPA: 0.23, range: 0.01–2.54, PAI-
1: 4.5 ng mg–1 protein, range: 1.46–15.3, P < 0.001) confirming
our previous results obtained with a group of 45 ovarian cancer
patients (Kuhn et al, 1994). Patients exhibiting uPA concentrations
below the cut-off value (2.0 ng mg–1 protein) had a statistical
survival advantage (n = 61, 53 months) over patients exhibiting
elevated uPA antigen (19 months; n = 25) (Figure 2). Similarly,
patients with antigen levels below the PAI-1 cut-off (27.5 ng mg–1
protein) had a median survival of 53 months (n = 61) compared to
19 months (n = 25) for patients above the PAI-1 cut-off (Figure 3).
Patients with both uPA and PAI-1 antigen content (n = 50) below
the respective cut-off values had also a statistically significant
survival advantage over patients with uPA and/or PAI-1 (n = 36)
above the respective cut-off (65 vs 20 months; P = 0.003). The
prognostic relevant factors of uPA, PAI-1, residual tumour mass,
nodal status, grading and ascites volume were weighted by Cox
multivariate analysis. Residual tumour mass (RR 4.5) and PAI-1
(RR 3.1) turned out to be the strongest, statistically independent
prognostic factors (Table 2) followed by the nodal status (P =
0.022, RR = 2.6). In another multivariate analysis, the individual
factors uPA and PAI-1 were removed from the analysis, but a
composite factor (‘both factors low’ vs ‘either factor high’) was
included. This composite factor was also of independent statistical
significance (P = 0.004, RR = 2.3).
Analysis of overall survival as a function of uPA and
PAI-1 in the presence and absence of residual tumour
mass
In the group of patients carrying residual tumour burden, only PAI-
1, but not uPA or uPA in combination with PAI-1, was of signifi-
cant prognostic value (P < 0.001). PAI-1 antigen below the cut-off
defined a group of patients (n = 33) with a median overall survival
of 29 months, in contrast to the group with PAI-1 above the cut-off
(n = 10) indicating a life expectancy of only 12 months. In the
group of patients with no macroscopically detectable residual
tumour mass (n = 43), both uPA and PAI-1 were of strong prog-
nostic relevance for overall survival. Median survival time of
patients with uPA below the cut-off (n = 32) was 74 months
compared to 26 months for patients with elevated uPA (n = 11; P =
0.0019). Patients with PAI-1 concentrations below the cut-off (n =
28; 74 months) had a remarkable survival advantage over patients
with PAI-1 above the cut-off (n = 15, 41 months, P = 0.019). The
combination of uPA and PAI-1, as defined above, was also of
prognostic strength (P = 0.0049) although it did not reach the
predictive power of uPA or PAI-1 alone.
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Figure 1 Overall survival of advanced ovarian cancer patients stage FIGO
IIIc (n = 86) as a function of residual tumour mass. Patients with no residual
tumour burden (n = 43) had a median survival time of 65 months compared
to 17 months for patients with residual tumour mass (n = 43). The difference
between the two groups exhibited statistical significance
Figure 2 Overall survival of advanced ovarian cancer patients stage FIGO
IIIc (n = 86) as a function of uPA antigen content in primary tumour tissue
extracts. Patients with uPA ≤ 2.0 ng mg–1 protein (n = 61) had a median
survival of 53 months compared to 19 months for patients with uPA 
> 2.0 ng mg–1 protein (n = 25). The difference between the two groups was
statistically significantUrokinase and its inhibitor PAI-1 in ovarian cancer 1749
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Time-varying prognostic impact of uPA, PAI-1 and
residual tumour mass
The statistical model of Gray (1992) was applied to describe the
change of the relative risk values for uPA, PAI-1 and residual
tumour mass over time (50 months). This type of analysis
disclosed that the prognostic influence of residual tumour mass
and PAI-1 considerably and constantly increased over time, with
PAI-1 reaching its peak at 2 years follow-up. There was almost no
change to the relatively low prognostic power of uPA over time
(Figure 4).
DISCUSSION
Several studies have been undertaken to identify and characterize
tumour biological factors in order to predict overall survival in
advanced ovarian cancer (Friedlaender et al, 1989; Berchuck et al,
1991; Tyson et al, 1991; Lage et al, 1992). So far none of these
factors explored was strong enough to allow translation into clin-
ical practice, thus leaving clinicians with the major traditional prog-
nostic factor residual tumour mass (Kuhn et al, 1993; Makar et al,
1995). In the past, the course of the disease has been improved by
more radical and refined surgical techniques in combination with
platinum- and paclitaxel-based chemotherapy; however, even
patients without residual tumour mass often experience unsatisfac-
tory early disease recurrence. In a recent study by Makar et al, the
clinical value of residual tumour mass in predicting overall survival
was consolidated for FIGO III patients, consistent with our
previous data (Kuhn et al, 1993; Makar et al, 1995).
A major new finding in our present analysis (n = 86) points to
the strong prognostic impact of the protease inhibitor PAI-1 in
FIGO IIIc patients with or without residual tumour mass. This
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Figure 3 Overall survival of advanced ovarian cancer patients stage FIGO
IIIc (n = 86) as a function of PAI-1 antigen content in primary tumour tissue
extracts. Patients with PAI-1 ≤ 27.5 ng mg–1 (n = 61) had a median survival of
53 months compared to 19 months for patients with PAI-1 > 27.5 ng mg–1
(n = 25). The difference between the two groups exhibited statistical
significance
Figure 4 Time variation of the relative risk related to uPA, PAI-1 and
residual tumour mass. Statistical evaluation of the relative risks of death
was conducted within a time frame of 50 months by using the time-varying
coefficient model of Gray (1992)
Table 2 Univariate and multivariate analysis of prognostic factors for survival in ovarian cancer
Variable Univariate Multivariate
P-value RR P-value RR
Residual tumour mass
with vs without < 0.001 3.9 < 0.001 4.5
(2.0–7.6)a (2.2–9.3)
PAI-1
≤ 27.5 vs > 27.5 ng mg–1 protein 0.012 2.1 < 0.001 3.1
(1.2–3.6) (1.7–5.7)
uPA
≤ 2.0 vs > 2.0 ng mg–1 protein 0.003 2.4 n.s.
1.4–4.3
Nodal status
N0 vs N1, Nx < 0.001 3.8 0.022 2.6
(1.7–8.2) (1.1–5.7)
Age
≤ 60 vs > 60 years 0.053 – n.s.
Grading
G1+G2 vs G3+G4 0.015 2.4 n.s.
(1.2–4.8)
Ascites volume
≤ 500 vs > 500 ml 0.034 1.8 n.s.
(1.0–3.2)
n.s. = not significant. aconfidence interval.1750 W Kuhn et al
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finding allows better selection of at risk patients in these clinically
important ovarian cancer subgroups according to elevated tumour
antigen level of PAI-1. In a variety of human solid cancers, special
attention has been paid to tumour-associated proteolytic factors
crucially implicated in tumour invasion and metastasis, such as
uPA and its inhibitor PAI-1 (Jänicke et al, 1989; Duffy et al, 1990;
Foekens et al, 1992; Grondahl-Hansen et al, 1993; Kuhn et al,
1994; Kobayashi et al, 1994; Nekarda et al, 1994; Hofmann et al,
1996). With this knowledge in mind, our group was the first to find
significantly elevated antigen levels of uPA and PAI-1 in breast
cancer tissue (Jänicke et al, 1989, 1991) to be associated with
disease recurrence or early death. Later it was shown that elevated
levels of these factors in cancer tissue of the gastrointestinal tract,
kidney, bladder, lung, brain, breast, cervix and ovary also indicate
a poor prognosis (Schmitt et al, 1997b).
This paper presents strong evidence that, in addition to residual
tumour mass, PAI-1 is a statistically independent prognostic factor
in FIGO IIIc patients (Kuhn et al, 1994). Even more important,
PAI-1 remains a strong, statistically relevant prognostic factor in
the subgroup of patients with residual tumour mass, thus allowing
discrimination of low- and high-risk patients. Despite the presence
of residual tumour mass, low PAI-1 antigen defined a favourable
group of patients with considerable survival advantage of more
than 17 months over patients with high PAI-1 values.
In the group of patients with no macroscopically detectable
residual tumour mass, both uPA and PAI-1 were of strong prog-
nostic relevance for overall survival. Similar to the patients with
residual tumour mass, elevated levels of PAI-1 and uPA allow one
to define patients who have a favourable prognosis with a survival
advantage of 33 and 48 months respectively. Van der Burg et al
(1996), who assessed a smaller number of FIGO III patients (eight
without and 36 with residual tumour mass), did not detect such an
effect. Aside from the smaller collective, a major difference in the
statistical methods applied may have been responsible for this
difference: to identify patients at risk, we used optimized cut-off
values (log-rank statistic) for uPA and PAI-1, whereas van der
Burg et al employed median values. The strong clinical impact of
uPA and PAI-1 in residual tumour-free patients has also been
shown in totally resected (R°) gastric cancer patients by our group
(Nekarda et al, 1994). The statistical significance of uPA and PAI-
1 for tumour-free patients in this type of cancer is similar to the
situation in tumour-free ovarian cancer.
For some types of cancer (Merkel and McGuire, 1990; Dettmar
et al, 1997), DNA ploidy and S phase fraction have been proposed
as prognostic markers. In our group of ovarian cancer patients,
none of these DNA parameters attained statistical significance, a
finding supported by the data of Kigawa et al (1993) and Kaern et
al (1994). On the other hand, we have shown that nuclear grade,
ascites volume and nodal status are of prognostic relevance in
FIGO IIIc patients, thus confirming data obtained by other study
groups (Burghardt et al, 1991; Scarabelli et al, 1995).
As noted above, a statistical approach, first described by Gray in
1992, has been applied in the present analysis to calculate the
change of the relative risk for early death over time (50 months)
associated with presence of residual tumour mass or elevated
levels of uPA or PAI-1. This type of analysis discloses that the
prognostic influence of residual tumour mass and PAI-1 increase
considerably over time, whereas that of uPA is not subject to
change. Our group previously applied Gray’s model to study the
time-varying impact of uPA and PAI-1 on prognosis (Schmitt et al,
1997a) in breast cancer. Similar to our new findings in ovarian
cancer stage FIGO IIIc, the prognostic impact of PAI-1 in breast
cancer increases over time, whereas that of uPA is significant for
the first 3 years only.
It is a common observation in solid malignant tumours that
elevated levels of uPA and its inhibitor PAI-1 indicate poor
outcome in cancer patients (Schmitt et al, 1997b). This clinical
observation is supported by tumour biological findings pointing to
a special role of PAI-1 in tumour invasion and metastasis, quite
apart from its function in inhibiting the proteolytic activity of the
protease uPA (Kanse et al, 1996; Stefansson and Lawrence, 1996;
Wei et al, 1996). PAI-1 modulates binding of uPAR (the receptor
for uPA, CD87) to vitronectin (Kanse et al, 1996) and binding of
vitronectin to the cellular integrin avb3 (Stefansson and Lawrence,
1996) thereby facilitating tumour cell migration and metastasis.
Along these lines, Liu et al (1995) have shown that co-expression
of uPA, PAI-1 and uPAR by tumour cells is necessary for focalized
and optimal invasion. Increases in PAI-1 are also associated with
angiogenesis (Barbareschi et al, 1995).
Selection of ovarian cancer FIGO IIIc patients in the subgroups
with or without residual tumour mass by the tumour biological
factors uPA and/or PAI-1 could lead to individualized therapeutic
regimens for patients at risk, thereby increasing the chance to
improve the course of the disease and predict therapy response,
especially for high-risk patients with residual tumour mass. New
therapeutical protocols that may be considered for these patients
suggest high-dose chemotherapy in combination with stem cell
support or secondary debulking procedures (Benedetti et al, 1995;
Van der Burg et al, 1995). Prior to transfer into clinical routine,
further validation of the impact of uPA and PAI-1 in ovarian cancer
prognosis is needed, which will require assessing larger, and
different, cancer patient groups. The predictive value should then
be determined by evaluating the therapy response of patients at
risk in a randomized trial.
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